Type your tag names separated by a space and hit enter

Transfusion Reaction

Basics

Description

  • Any acute or subacute adverse reaction that develops as a consequence of the administration of blood components
  • Types include the following:
    • Acute reactions: hemolytic, febrile, allergic, anaphylactic, septic, transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO)
    • Delayed reactions: delayed hemolytic, transfusion-associated graft-versus-host disease (TA-GVHD)
    • Late complications of transfusion: infection, alloimmunization, iron overload

Epidemiology

  • 1% of pediatric blood product recipients develop some type of transfusion reaction.
  • Transfusion associated with death in 1 in 200,000 to 420,000 transfused units

Pathophysiology

  • Acute hemolytic transfusion reaction
    • Antigen–antibody interaction leads to complement activation on the surface of the transfused RBCs, resulting in acute intravascular hemolysis and vasomotor instability.
    • Usually ABO blood group incompatibility
    • Most commonly due to medical error
  • Febrile nonhemolytic transfusion reaction (FNHTR)
    • Cytokines released by leukocytes in the product
    • 40% of patients with one febrile reaction will have a subsequent one.
  • Urticarial (allergic)
    • IgE-mediated
    • Recipient allergic response to donor plasma proteins or other constituents of plasma
    • Sporadic and donor dependent
  • Anaphylactic
    • Overwhelming acute allergic reaction; can be mediated by anti-IgA formed by a recipient who is IgA deficient and receives blood products containing IgA
  • Bacterial sepsis
    • Intravascular infusion of viable bacteria and endotoxins leads to fever, chills, and/or acute septic shock.
    • Contaminated blood product; most commonly a platelet product near the end of shelf life
  • Delayed hemolytic transfusion reaction (DHTR)
    • Previously transfused patients who are sensitized to a minor blood group antigen, especially Jka or Jkb (Kidd antigen), develop an anamnestic response on reexposure.
    • Antibody is below detectable levels in antibody screen and crossmatch; after transfusion, titers rise (usually within 2 to 10 days) and extravascular hemolysis occurs.
  • TRALI
    • Antileukocyte antibodies or neutrophil-activating factors in transfused product interact with recipient neutrophils, causing leukocyte aggregates that deposit in the lung.
    • Multiparous female donors with HLA sensitization often are implicated.
  • TACO
    • Circulatory overload leading to heart failure
    • Administration of an excessive volume of a blood product or infusion at an excessive rate
  • TA-GVHD
    • Patients with inherited or acquired T-cell immunodeficiency can develop TA-GVHD from transfused immunocompetent T cells.
    • Can also occur if the donor and recipient are related and share HLA types

Diagnosis

History

  • Acute hemolytic
    • Fever/chills
    • Abdominal or flank pain
    • Pink or tea-colored urine
    • Tachycardia
    • Hypotension
    • Oliguria
  • FNHTR
    • Fever, chills 1 to 6 hours after transfusion
  • Urticarial
    • Urticaria
    • Flushing
    • Pruritus
  • Anaphylactic
    • Urticaria
    • Bronchospasm
    • Hypotension
  • Bacterial sepsis
    • Fever
    • Chills
    • Hypotension
  • DHTR
    • Fever
    • Malaise
    • Dark urine
    • Jaundice
    • Shock (rarely)
    • Renal failure 2 to 10 days after transfusion
  • TRALI
    • Acute dyspnea, tachypnea, rales, decreased oxygenation within 6 hours of transfusion
  • TACO
    • Hypertension
    • Dyspnea
    • Rales
    • Cardiac arrhythmia
  • TA-GVHD
    • Fever
    • Rash
    • Diarrhea
    • Cough 4 to 30 days after transfusion

Diagnostic Tests and Interpretation

Initial Tests

  • Acute hemolytic
    • Direct Coombs test: positive
    • CBC: anemia
    • Urinalysis: hemoglobinuria
    • Prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen, fibrin split products: disseminated intravascular coagulation (DIC)
  • FNHTR
    • Direct Coombs test: negative or no change from pretransfusion
    • Immediate Gram stain of the product
    • Blood culture of the patient and product
    • All results should be negative; a diagnosis of exclusion
  • Urticarial
    • No specific testing
  • Anaphylactic
    • IgA level in recipient. If undetectable, test for anti-IgA antibody (of the IgE class).
  • Bacterial sepsis
    • Immediate Gram stain and blood culture of the transfused product: result positive for bacteria
  • DHTR
    • CBC: anemia
    • Bilirubin: elevated
    • Indirect Coombs test (antibody screen): positive
    • Direct Coombs test: positive (mixed field) if done early
  • TRALI
    • Leukocyte antibody testing in the implicated donor(s)
  • Chest radiograph: increased pulmonary vascular markings or infiltrates for hypervolemia (TACO) and TRALI

Treatment

General Measures

  • Acute hemolytic
    • Stop transfusion immediately.
    • Supportive care with hydration, pressors, and diuretics to maintain circulation and urine output
  • FNHTR
    • Stop transfusion.
    • Antipyretics (acetaminophen)
    • Demerol for severe chills and rigors
    • May resume transfusion if patient is stable and acute hemolytic transfusion reaction and bacterial sepsis are ruled out
  • Urticarial
    • Stop transfusion.
    • Antihistamine (diphenhydramine)
    • Steroids or epinephrine in severe reactions
    • Transfusion may be resumed if mild reaction.
  • Anaphylactic
    • Epinephrine
    • IV fluids, pressors
    • Respiratory support
  • Bacterial sepsis
    • Stop transfusion.
    • Fluids if hypotensive
    • Antibiotics to eradicate Staphylococcus and Gram negatives including Yersinia species
  • DHTR
    • Depends on degree of hemolysis; if profound, management as acute hemolytic reaction. If mild, no therapy may be needed.
  • TRALI
    • Supportive care; usually resolves in 12 to 24 hours
  • TACO: diuretics (furosemide)
  • TA-GVHD: no treatment; almost always fatal
  • General prevention
    • Acute hemolytic
      • Proper labeling of blood specimens and products and adherence to procedures for correct identification of product and recipient will eliminate most acute hemolytic transfusion reactions.
    • FNHTR
      • Administration of leukodepleted blood products, especially for long-term transfused patients who have a high incidence of febrile transfusion reactions
      • No evidence to support premedication with acetaminophen or diphenhydramine to prevent FNHTR
    • Urticarial
      • Administration of washed erythrocyte products (in patients with repeated or severe allergic reactions)
      • No conclusive evidence to support premedication with antihistamines
    • Anaphylactic
      • If due to anti-IgA in an IgA-deficient recipient, provision of IgA-deficient products may be possible.
    • Bacterial sepsis
      • Sterile technique in blood collection, storage, and administration; inspection of product before transfusion
      • Bacterial screening of platelet products before they are transfused
    • DHTR
      • Appropriately performed antibody screen and crossmatch as pretransfusion testing
      • Check blood bank records for previous antibodies.
    • TRALI
      • Deferral of donors is implicated in proven TRALI cases.
    • TACO
      • Administer appropriate volumes (typically 10 to 15 mL/kg) at appropriate rate, usually over 3 to 4 hours unless hypovolemic or actively bleeding.
      • Patients with chronic anemia are euvolemic and should be transfused with smaller volumes over longer time periods.
    • TA-GVHD
      • Patients at risk (immunocompromised, neonates) must receive irradiated blood products.

Ongoing Care

Complications

  • Posttransfusion hepatitis: caused by hepatitis B or C viruses, others
  • AIDS: caused by HIV
  • Cytomegalovirus (CMV)
    • Symptomatic infection in patients with inherited or acquired immunodeficiency states, premature neonates
    • These individuals should receive CMV-safe products.
  • Other transfusion-transmissible infections
    • Epstein-Barr virus, syphilis, malaria, toxoplasmosis, human T-cell lymphotropic virus I (HTLV-I), Chagas disease, babesiosis, filariasis, West Nile virus, parvovirus B19
  • Alloimmunization
    • Formation of antibodies to erythrocyte, platelet, and HLA antigens can develop in some multiply transfused patients; may cause delays in pretransfusion testing, febrile transfusion reactions, DHTR, and platelet transfusion refractoriness
    • HLA alloimmunization may also affect eligibility and organ procurement for solid organ transplantation.
  • Iron overload
    • Long-term transfusion recipients will accumulate iron as a by-product of erythrocyte breakdown.
    • An iron-chelating drug will enhance its excretion.

Additional Reading

  1. Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388(10061):2825–2836.  [PMID:27083327]
  2. Lindholm PF, Annen K, Ramsey G. Approaches to minimize infection risk in blood banking and transfusion practice. Infect Disord Drug Targets. 2011;11(1):45–56.  [PMID:21303341]
  3. Slonim AD, Joseph JG, Turenne WM, et al. Blood transfusions in children: a multi-institutional analysis of practices and complications. Transfusion. 2008;48(1):73–80.  [PMID:17894792]
  4. Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion. 2007;47(6):1089–1096.  [PMID:17524101]
  5. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113(15):3406–3417.  [PMID:19188662]

Codes

ICD-9

  • 999.80 Transfusion reaction, unspecified
  • 999.83 Hemolytic transfusion reaction, incompatibility unspecified
  • 999.89 Other transfusion reaction
  • 518.7 Transfusion related acute lung injury (TRALI)
  • 999.41 Anaphylactic reaction due to administration of blood and blood products
  • 999.70 Rh incompatibility reaction, unspecified
  • 999.60 ABO incompatibility reaction, unspecified

ICD-10

  • T80.92XA Unspecified transfusion reaction, initial encounter
  • T80.919A Hemolytic transfusion reaction, unspecified incompatibility, unspecified as acute or delayed, initial encounter
  • R50.84 Febrile nonhemolytic transfusion reaction
  • J95.84 Transfusion-related acute lung injury (TRALI)
  • T80.39XA Oth ABO incompat react due to tranfs of bld/bld prod, init
  • T80.49XA Oth Rh incompat reaction due to tranfs of bld/bld prod, init
  • T80.89XA Oth comp fol infusion, transfuse and theraputc inject, init

SNOMED

  • 82545002 Blood transfusion reaction (disorder)
  • 39778006 Hemolytic transfusion reaction (disorder)
  • 73301000 febrile transfusion reaction (disorder)
  • 389078002 Transfusion related acute lung injury (disorder)
  • 341009 ABO incompatibility reaction
  • 88924008 Rh incompatibility reaction (disorder)

FAQ

  • Q: What is the risk of acquiring certain viral infections?
  • A: Hepatitis B: 1:300,000 transfused units; hepatitis C: 1:1,800,000 transfused units; HIV: 1:2,300,000 transfused units
  • Q: What is the risk of developing bacterial sepsis?
  • A: 1:1,000,000 red cell units; 1:13,000 to 100,000 platelet units
  • Q: Is directed donor blood safer?
  • A: No. There is no evidence that the infection risk is lower, and some studies suggest that the infection risk may be higher.
  • Q: Is it safe to give a transfusion to a patient with fever?
  • A: Yes. However, if the temperature rises during the transfusion or if symptoms such as chills or hypotension develop, the transfusion should be stopped and the patient evaluated for a transfusion reaction.

Authors

Kristin A. Shimano, MD


© Wolters Kluwer Health Lippincott Williams & Wilkins

Transfusion Reaction is a sample topic from the 5-Minute Pediatric Consult.

To view other topics, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Learn more.

Citation

Cabana, Michael D., editor. "Transfusion Reaction." 5-Minute Pediatric Consult, 8th ed., Wolters Kluwer, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/5-Minute-Pediatric-Consult/617571/all/Transfusion_Reaction.
Transfusion Reaction. In: Cabana MD, ed. 5-Minute Pediatric Consult. 8th ed. Wolters Kluwer; 2019. https://peds.unboundmedicine.com/pedscentral/view/5-Minute-Pediatric-Consult/617571/all/Transfusion_Reaction. Accessed April 23, 2019.
Transfusion Reaction. (2019). In Cabana, M. D. (Ed.), 5-Minute Pediatric Consult. Available from https://peds.unboundmedicine.com/pedscentral/view/5-Minute-Pediatric-Consult/617571/all/Transfusion_Reaction
Transfusion Reaction [Internet]. In: Cabana MD, editors. 5-Minute Pediatric Consult. Wolters Kluwer; 2019. [cited 2019 April 23]. Available from: https://peds.unboundmedicine.com/pedscentral/view/5-Minute-Pediatric-Consult/617571/all/Transfusion_Reaction.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Transfusion Reaction ID - 617571 ED - Cabana,Michael D, BT - 5-Minute Pediatric Consult UR - https://peds.unboundmedicine.com/pedscentral/view/5-Minute-Pediatric-Consult/617571/all/Transfusion_Reaction PB - Wolters Kluwer ET - 8 DB - Pediatrics Central DP - Unbound Medicine ER -